{"product_id":"tlsi-ansoff-analysis","title":"(TLSI) TriSalus Life Sciences, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis TriSalus Life Sciences, Inc. Ansoff Matrix Analysis helps you quickly assess growth options across market penetration, market development, product development, and diversification in a concise matrix format; the page already includes a real preview\/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis for strategy, investing, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTriNav Infusion System in liver tumor care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTriNav is TriSalus Life Sciences, Inc.’s existing hepatic arterial infusion system for liver tumors, so market penetration means more use in current interventional oncology settings. The goal is simple: more procedures, more repeat use, and broader adoption inside teams already treating liver disease. That matters because liver cancer remains a major global burden, with about 865,000 new cases and 760,000 deaths each year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePancreatic Retrograde Venous Infusion System in pancreatic tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc.'s pancreatic retrograde venous infusion system is an existing pancreatic-tumor delivery platform, so penetration depends on getting more use inside the current pancreatic cancer market. The American Cancer Society projected about 67,440 new U.S. pancreatic cancer cases and 51,980 deaths in 2025, underscoring the unmet need. Adoption will hinge on clinician familiarity, procedural fit, and repeat use in pancreatic tumor programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHepatic arterial infusion workflow adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. can drive market penetration by making hepatic arterial infusion a standard step in existing liver-tumor pathways at interventional centers. The strongest users are the U.S. centers already treating the 43,000 new liver and intrahepatic bile duct cancer cases diagnosed in 2025, where adoption can rise by fitting into current catheter-based workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInterventional oncology center utilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. sells into specialized interventional oncology centers, so market penetration means winning a larger share of procedures and accounts inside a fixed, high-value niche. That raises installed base without changing the product mix. In 2025, the U.S. interventional oncology channel stayed concentrated, so each new center added can lift use fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand use inside existing cancer centers\u003c\/li\u003e\n\u003cli\u003eGrow share without new products\u003c\/li\u003e\n\u003cli\u003eFocus on repeat procedures and adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHCC and pancreatic cancer treatment focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. is focused on liver and pancreatic cancers, so market penetration means selling deeper into the same disease areas where its products already fit. That keeps growth tied to the existing addressable market, not a new one.\u003c\/p\u003e\n\u003cp\u003eIn the U.S., pancreatic cancer is projected to drive about 67,440 new cases and 51,750 deaths in 2025, while liver cancer remains a high-need solid tumor area. That makes HCC and pancreatic cancer a clear fit for repeat use, better adoption, and share gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse existing oncology fit\u003c\/li\u003e\n\u003cli\u003eGrow within current tumor types\u003c\/li\u003e\n\u003cli\u003eTarget the same care paths\u003c\/li\u003e\n\u003cli\u003eExpand share, not scope\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTriSalus Grows by Deepening Share in High-Volume Cancer Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. market penetration means selling TriNav and the pancreatic infusion system more often inside the same liver and pancreatic cancer centers. U.S. 2025 case loads stay large: 43,090 liver and intrahepatic bile duct cancers and 67,440 pancreatic cancers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 U.S.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver cases\u003c\/td\u003e\n\u003ctd\u003e43,090\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic cases\u003c\/td\u003e\n\u003ctd\u003e67,440\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSo growth comes from more procedures, more repeat use, and higher share in existing interventional oncology sites.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing TriSalus Life Sciences, Inc.’s growth strategy across existing and new markets and products\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear TriSalus Life Sciences Ansoff Matrix to quickly relieve growth-planning confusion across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists credible primary and secondary sources to fast-verify TriSalus Life Sciences growth-path assumptions for Ansoff Matrix decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdditional liver-tumor centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTriNav fits market development because TriSalus Life Sciences, Inc. can keep the same device while adding more liver-tumor centers that already do liver-directed procedures. The U.S. expected 2025 burden was about 42,240 new liver and intrahepatic bile duct cancer cases and 30,090 deaths, showing a large addressable pool for center expansion. More center adoption can widen procedure volume without changing the product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdditional pancreatic cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences can push its pancreatic infusion system into more pancreatic cancer programs, expanding an existing product into new care sites. In the U.S., pancreatic cancer still caused about 67,440 new cases and 51,750 deaths in 2025, so broader center access can matter fast. More programs can mean more eligible patients and wider clinical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader interventional radiology reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. can grow by selling its procedure-based cancer products to more interventional radiology and interventional oncology teams, not by changing the portfolio. In the U.S., the American Cancer Society estimated 2.0 million new cancer cases in 2025, and many liver, pancreas, and metastatic procedures are already routed through these specialty teams. That broadens reach while keeping the same clinical workflow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTertiary cancer hospital expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. can push its existing delivery systems into more tertiary cancer hospitals with liver and pancreatic programs, so this is market development, not a new-product play. The move broadens institutional coverage and can scale sales through the same clinical workflow. In 2025, the U.S. still had a limited pool of high-acuity cancer centers, so each new account can matter more. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing products\u003c\/li\u003e\n\u003cli\u003eAims at tertiary centers\u003c\/li\u003e\n\u003cli\u003eGrows hospital coverage\u003c\/li\u003e\n\u003cli\u003eNeeds no new launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReferral-network expansion in liver and pancreas care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReferral-network expansion fits market development for TriSalus Life Sciences, Inc. because the same delivery platforms can reach new oncology networks without changing the core device. That matters in liver and pancreatic cancer, where care is concentrated in specialty pathways; the American Cancer Society estimated 66,440 new pancreatic cases and 41,630 liver and intrahepatic bile duct cases in 2025.\u003c\/p\u003e\n\u003cp\u003eFor TriSalus Life Sciences, Inc., the growth lever is access, not product redesign: more referrals into interventional radiology, surgical oncology, and academic centers can widen use of existing devices across a larger patient pool. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame device, new referral channels.\u003c\/li\u003e\n\u003cli\u003eBest fit: specialty cancer pathways.\u003c\/li\u003e\n\u003cli\u003e2025 U.S. cases: 66,440 pancreas.\u003c\/li\u003e\n\u003cli\u003e2025 U.S. cases: 41,630 liver.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTriSalus Grows by Reaching More Cancer Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. fits market development because it can sell the same TriNav system into more liver and pancreatic cancer centers without changing the device. The American Cancer Society estimated 2025 U.S. cases at 42,240 for liver and intrahepatic bile duct cancer and 67,440 for pancreatic cancer, so new center access can lift use fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025 U.S.\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver and intrahepatic bile duct cases\u003c\/td\u003e\n\u003ctd\u003e42,240\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic cases\u003c\/td\u003e\n\u003ctd\u003e67,440\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowth lever\u003c\/td\u003e\n\u003ctd\u003eNew centers, same device\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTriSalus Life Sciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD-101 for hepatocellular carcinoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD-101 is TriSalus Life Sciences, Inc.'s investigational immunotherapeutic, and testing it in hepatocellular carcinoma is product development inside an existing liver-cancer market. Hepatocellular carcinoma makes up about 75% to 85% of primary liver cancers, which still caused roughly 866,000 new cases and 760,000 deaths worldwide in 2022. TriSalus is pairing SD-101 with pressure-enabled delivery to try to improve tumor exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD-101 for intrahepatic cholangiocarcinoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD-101 for intrahepatic cholangiocarcinoma is product development, since TriSalus Life Sciences, Inc. is adding a new therapy to an existing liver-cancer market. The move extends its hepatobiliary oncology platform into a hard-to-treat tumor with limited options; first-line standard care still yields median overall survival near 12.8 months in TOPAZ-1. That makes pipeline expansion into iCCA clinically and commercially meaningful.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD-101 for pancreatic ductal adenocarcinoma with liver metastases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD-101 for pancreatic ductal adenocarcinoma with liver metastases is a Product Development move in TriSalus Life Sciences, Inc. Ansoff Matrix: a new therapy for a market the company already serves in pancreatic cancer. About 67,440 U.S. pancreatic cancer cases are expected in 2025, and liver spread is common in advanced disease, so the fit is clear.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSD-101 for primary pancreatic cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePrimary pancreatic cancer is a core TriSalus target, and product development means advancing SD-101 as a new immunotherapy for that same market. With about 67,440 U.S. pancreatic cancer cases projected in 2025 and a 5-year survival near 13%, SD-101 can add value by pairing with TriSalus' pancreatic delivery system.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, new therapy\u003c\/li\u003e\n\u003cli\u003eFits pancreatic delivery platform\u003c\/li\u003e\n\u003cli\u003eTargets high unmet need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSD-101 for liver-metastatic uveal melanoma and colorectal cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSD-101 is a second-line product development step for TriSalus Life Sciences, Inc., extending the same liver-directed delivery concept into liver-metastatic uveal melanoma and colorectal cancer. This matters because about 50% of colorectal cancer patients and nearly 90% of uveal melanoma patients with metastatic disease can develop liver involvement, so the target set is clinically large.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew uses for the same delivery platform\u003c\/li\u003e\n\u003cli\u003eTargets cancers already in the liver\u003c\/li\u003e\n\u003cli\u003eBroadens the portfolio without changing core tech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTriSalus Expands SD-101 into High-Need Cancer Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. is using SD-101 to extend its existing liver and pancreatic oncology platform into adjacent indications, which is classic Product Development. The move targets high-unmet-need tumors with large 2025 case bases, including about 67,440 U.S. pancreatic cancer cases and persistent liver involvement in metastatic disease.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic cancer\u003c\/td\u003e\n\u003ctd\u003e67,440 U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCC\u003c\/td\u003e\n\u003ctd\u003e~866,000 new global cases in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD-101 in uveal melanoma with liver metastases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD-101 in uveal melanoma with liver metastases is diversification for TriSalus Life Sciences, Inc. because uveal melanoma is outside its core liver and pancreatic cancer focus, yet the liver-metastatic setting still fits its intra-arterial delivery platform. Uveal melanoma is rare, at about 5–7 cases per 1 million people each year, so this move opens a new oncology niche with a new immunotherapy asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSD-101 in colorectal cancer with liver metastases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD-101 in colorectal cancer with liver metastases is diversification into a new market and a new product path at the same time. Colorectal cancer is outside TriSalus Life Sciences, Inc.'s core hepatobiliary and pancreatic focus, and about 50% of colorectal cancer patients develop liver metastases, a large addressable segment. This broadens the company’s reach fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader metastatic solid-tumor oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSD-101 already spans more than one cancer type, so TriSalus Life Sciences, Inc. is not just deepening one niche; it is moving into broader metastatic solid-tumor markets. That is classic diversification: one platform, multiple non-core disease segments. With solid tumors making up about 90% of all cancers worldwide, the addressable pool is far larger than a single indication. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePressure-enabled immunotherapy platform expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTriSalus is diversifying beyond devices by pairing pressure-enabled delivery with immunotherapy, a platform that can move into new solid-tumor markets. That matters in pancreatic cancer, where U.S. cases are about 67,000 a year and 5-year survival is near 13%, so better drug delivery can have high impact.\u003c\/p\u003e\n\u003cp\u003eThe model scales by combining its delivery tech with novel therapeutics, not just selling hardware.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands into new cancer indications\u003c\/li\u003e\n\u003cli\u003eBlends device and drug value\u003c\/li\u003e\n\u003cli\u003eTargets hard-to-treat tumors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core cancer referral pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. can diversify by reaching non-core cancer referral paths in uveal melanoma and colorectal cancer with liver metastases, which draw on different oncology networks than its liver and pancreatic base. Uveal melanoma is rare, with about 5,000 U.S. cases a year, while colorectal cancer caused about 52,550 U.S. deaths in 2023, so these pathways can widen clinician reach. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew referral networks\u003c\/li\u003e\n\u003cli\u003eDifferent tumor specialists\u003c\/li\u003e\n\u003cli\u003eBroader therapeutic use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTriSalus Expands SD-101 Into Rare and High-Volume Cancer Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTriSalus Life Sciences, Inc. is diversifying by taking SD-101 into non-core metastatic solid tumors: uveal melanoma and colorectal cancer with liver metastases. Uveal melanoma is rare at about 5-7 cases per 1 million a year, while about 50% of colorectal cancer patients develop liver metastases, so the move widens both indication and referral reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUveal melanoma\u003c\/td\u003e\n\u003ctd\u003e5-7\/million\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRC liver mets\u003c\/td\u003e\n\u003ctd\u003e~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235065700617,"sku":"tlsi-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tlsi-ansoff-matrix.webp?v=1785733711","url":"https:\/\/dcfanalyst.com\/products\/tlsi-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}